Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
British Journal of Cancer|January 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistryLisa Vermij, Jan J Jobsen, Alicia León-Castillo, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Gynecologic Oncology|March 3, 2023
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancerFélix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, et al.
Molecular Cancer|August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker researchAurélie Moniot, Christophe Schneider, Laure Chardin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant ChemotherapyElisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau, et al.
NPJ Genomic Medicine|April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP eraFélix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trialFélix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Bulletin Du Cancer|February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 13